Effect of Cabazitaxel on the QTc Interval in Cancer Patients
Status:
Completed
Trial end date:
2011-11-01
Target enrollment:
Participant gender:
Summary
Primary Objective:
- To assess the potential effect on QTcF interval (QTc Fridericia) of cabazitaxel in
cancer patients
Secondary Objectives:
- To assess the effects of cabazitaxel on heart rate (HR), QT, QTcB (Bazett's correction),
and QTcN (population specific correction) intervals
- To assess the clinical safety of cabazitaxel
- To assess cabazitaxel plasma concentrations at Cycle 1 at early timepoints (during
infusion and up to 5h post end of infusion)